

2017 VC Deals

A Sampling of the Year's Venture Capital Transactions

February 20, 2018




In 2017 Morse once again represented its clients in a range of venture capital transactions, including convertible note financings, equity investments, and sales of preferred stock. Our VC attorneys counseled companies in an array of industries, including biotechnology, custom clothing, and medical devices, among others.

	<p>Represented EnBiotix, a product-focused bioengineering company commercializing anti-infective inventions, in its Convertible Note Financing.</p>
	<p>Represented Fuel For Fire, a health and nutrition retailer, in the Sale of Series D Preferred Stock.</p>
	<p>Represented Orionis Biosciences, a company specializing in the development of new drugs for the treatment of certain autoimmune diseases and pathologies linked to certain types of cancer, in its Bridge Note Financing.</p>

	<p>Represented Privy, a platform that empowers marketers to build more customer relationships, in its Series Seed-2 Financing.</p>
	<p>Represented Cristcot, a global life sciences company focusing on unique drug delivery systems, combination products and specialty drug formulations, in its Convertible Note Financing.</p>
	<p>Represented Manus Bio, an interdisciplinary team dedicated to the sustainable production of quality plant-based ingredients, in its Series A Financing.</p>
	<p>Represented Accomplish Ventures, a seed-led venture capital firm, in its Equity Investment into Tive, Inc.</p>
	<p>Represented iSpecimen, the marketplace for human biospecimens, in its Convertible Note Financing.</p>

	<p>Represented Novellus, an early stage biotechnology company, in its Convertible Note Financing.</p>
	<p>Represented SciAps, a Boston-based instrumentation company specializing in portable analytical instruments, in its Series C Financing.</p>
	<p>Represented Connected Home Care, a provider of non-medical home care and companionship services for elders who want to live at home, in its Series A Follow-On Financing.</p>
	<p>Represented dRx Capital, an investor in early-stage companies in the digital medicine industry, in its Series C-1 Follow-On Financing of Omada Health.</p>
	<p>Represented First Light Biosciences, a developer of automated medical diagnostic products for rapid, sensitive, and cost-effective detection of Healthcare Associated Infections, in a Series A Preferred Financing.</p>

 The logo for BOW & DRAPE, with 'BOW & DRAPE' in a large, bold, black, sans-serif font and 'NEW YORK' in a smaller, black, sans-serif font below it.	<p>Represented Bow & Drape, a custom clothing retailer, in its Convertible Note Financing.</p>
---	---